[{"id":"pazopanib","kind":"drug","name":"Pazopanib","route":"/drugs/pazopanib/","commit":"9cbd69eefa","date":"2026-09-10","author":"Jude Gomila","message":"Primary source links (FDA label via DailyMed) for a fourth batch of thirty approved products","file":"src/data/spikes/sarcoma.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"FDA label (DailyMed)\", url: \"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Pazopanib\" }]"}]},{"id":"pazopanib","kind":"drug","name":"Pazopanib","route":"/drugs/pazopanib/","commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"class"},{"field":"props"},{"field":"management"},{"field":"pairs"},{"field":"food"},{"field":"hepatic"},{"field":"source"}]},{"id":"pazopanib","kind":"drug","name":"Pazopanib","route":"/drugs/pazopanib/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/spikes/sarcoma.ts","type":"changed","fields":[{"field":"tldr","before":"\"The only multi-kinase inhibitor approved for soft-tissue sarcoma (excluding fat-derived tumours), after chemotherapy fails.\"","after":"\"Pazopanib is the only multi-kinase inhibitor approved for soft-tissue sarcoma (excluding fat-derived tumours), used after chemotherapy fails.\""}]},{"id":"pazopanib","kind":"drug","name":"Pazopanib","route":"/drugs/pazopanib/","commit":"2997dc2520","date":"2026-09-08","author":"Jude Gomila","message":"Deep cancer spikes: DLBCL, multiple myeloma, Hodgkin lymphoma, sarcoma, neuroblastoma (135 new entities with structured outcomes, dosing, to","file":"src/data/spikes/sarcoma.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"brand"},{"field":"modality"},{"field":"status"},{"field":"wikipedia"},{"field":"tldr"},{"field":"summary"},{"field":"mechanism"},{"field":"dosing"},{"field":"toxicity"},{"field":"approvals"},{"field":"targets"},{"field":"technologies"},{"field":"companies"},{"field":"cancers"}]}]